Jean-Michel Dogné Selected Research

Carbonic Anhydrases (Carbonic Anhydrase)

6/2011	Specific inhibition of carbonic anhydrase IX activity enhances the in vivo therapeutic effect of tumor irradiation.
12/2008	Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation.
6/2008	Carbonic anhydrase inhibitors: bioreductive nitro-containing sulfonamides with selectivity for targeting the tumor associated isoforms IX and XII.
11/2006	Targeting tumor-associated carbonic anhydrase IX in cancer therapy.
5/2006	Indanesulfonamides as carbonic anhydrase inhibitors. Toward structure-based design of selective inhibitors of the tumor-associated isozyme CA IX.
3/2005	Carbonic anhydrase inhibitors: synthesis and inhibition of cytosolic/membrane-associated carbonic anhydrase isozymes I, II, and IX with sulfonamides incorporating hydrazino moieties.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jean-Michel Dogné Research Topics

Disease

21	Thrombosis (Thrombus) 01/2023 - 03/2003
19	Neoplasms (Cancer) 05/2024 - 08/2004
19	COVID-19 01/2023 - 01/2020
10	Activated Protein C Resistance (APC Resistance) 09/2022 - 12/2012
10	Hemorrhage 01/2018 - 06/2008
8	Thrombocytopenia (Thrombopenia) 01/2023 - 06/2010
8	Atherosclerosis 01/2018 - 12/2005
7	Venous Thromboembolism 09/2022 - 01/2013
7	Myocardial Infarction 06/2014 - 04/2004
7	Inflammation (Inflammations) 11/2013 - 08/2004
5	Infections 04/2024 - 03/2021
5	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 05/2020 - 05/2016
5	Hypoxia (Hypoxemia) 11/2013 - 11/2006
4	Hemolysis 10/2018 - 01/2014
4	Stroke (Strokes) 01/2014 - 01/2005
4	Shock 07/2006 - 08/2003
4	Asthma (Bronchial Asthma) 03/2006 - 01/2002
3	Breakthrough Infections 04/2024 - 01/2023
3	Drug-Related Side Effects and Adverse Reactions 11/2023 - 01/2008
3	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 07/2019 - 09/2015
3	Disseminated Intravascular Coagulation 02/2017 - 03/2014
3	Pain (Aches) 08/2015 - 01/2007
3	Pulmonary Embolism 01/2006 - 09/2004
3	Pulmonary Hypertension 01/2005 - 08/2003
2	Pericarditis 11/2023 - 01/2023
2	Protein S Deficiency (Deficiency, Protein S) 09/2022 - 09/2022
2	Inborn Genetic Diseases (Disease, Hereditary) 09/2022 - 09/2022
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2017 - 07/2014
2	Atrial Fibrillation 10/2014 - 01/2014
2	Tics (Tic) 01/2014 - 03/2012
2	Cardiovascular Diseases (Cardiovascular Disease) 04/2010 - 09/2009
2	Epilepsy (Aura) 12/2008 - 01/2007

Drug/Important Bio-Agent (IBA)

12	ThromboxanesIBA 01/2016 - 01/2002
10	Thrombin FDA Link 03/2022 - 03/2012
9	AntibodiesIBA 04/2024 - 01/2020
9	AntigensIBA 04/2024 - 01/2020
9	AnticoagulantsIBA 02/2021 - 06/2008
8	Protein CIBA 09/2022 - 01/2014
7	VaccinesIBA 04/2024 - 01/2021
7	Biomarkers (Surrogate Marker)IBA 05/2020 - 01/2005
6	RivaroxabanIBA 02/2021 - 12/2012
6	Dabigatran FDA Link 02/2021 - 05/2012
6	Heparin (Liquaemin)FDA LinkGeneric 12/2018 - 06/2010
6	N- terbutyl- N'- (2- (4'- methylphenylamino)- 5- nitrobenzenesulfonyl)ureaIBA 01/2016 - 01/2004
6	Carbonic Anhydrases (Carbonic Anhydrase)IBA 06/2011 - 03/2005
6	Protein Isoforms (Isoforms)IBA 02/2009 - 01/2006
5	Neutralizing AntibodiesIBA 04/2024 - 01/2021
5	BNT162 VaccineIBA 01/2023 - 01/2021
5	bcr-abl Fusion ProteinsIBA 05/2020 - 05/2016
5	Thromboxane A2 (A2, Thromboxane)IBA 09/2009 - 01/2002
5	IsoenzymesIBA 02/2009 - 03/2005
4	Proteins (Proteins, Gene)FDA Link 11/2022 - 03/2005
4	Contraceptive Agents (Contraceptives)IBA 03/2022 - 01/2020
4	SteroidsIBA 03/2022 - 01/2020
4	Immunoglobulin G (IgG)IBA 12/2021 - 11/2020
4	ponatinibIBA 01/2020 - 05/2016
4	Thromboxane Receptors (Thromboxane Receptor)IBA 01/2016 - 01/2002
4	ferric chlorideIBA 04/2005 - 05/2004
3	Indicators and Reagents (Reagents)IBA 03/2022 - 05/2012
3	apixabanIBA 02/2021 - 01/2014
3	nilotinib FDA Link 01/2020 - 01/2017
3	Dasatinib (BMS 354825)FDA Link 01/2020 - 01/2017
3	eculizumab FDA Link 07/2019 - 09/2015
3	Thromboplastin (Tissue Factor)IBA 02/2017 - 01/2013
3	Epoprostenol (Prostacyclin)FDA LinkGeneric 09/2009 - 12/2005
3	IsoprostanesIBA 09/2009 - 12/2005
3	SulfonamidesIBA 06/2008 - 11/2006
3	EnzymesIBA 06/2008 - 01/2007
3	Arachidonic Acid (Vitamin F)IBA 06/2006 - 01/2002
3	LeukotrienesIBA 03/2006 - 01/2002
3	ProstaglandinsIBA 03/2006 - 01/2002
2	fezolinetantIBA 05/2024 - 11/2023
2	mRNA VaccinesIBA 01/2023 - 01/2023
2	Messenger RNA (mRNA)IBA 01/2023 - 09/2021
2	ChAdOx1 nCoV-19IBA 11/2022 - 01/2021
2	Factor VIII (Coagulation Factor VIII)IBA 09/2022 - 09/2022
2	Hormones (Hormone)IBA 09/2022 - 09/2022
2	factor V Hong KongIBA 09/2022 - 09/2022
2	factor V CambridgeIBA 09/2022 - 09/2022
2	A-factor (Streptomyces)IBA 09/2022 - 09/2022
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 01/2022 - 05/2021
2	Intravenous Immunoglobulins (IVIG)FDA Link 12/2021 - 12/2021
2	Combined Oral ContraceptivesIBA 08/2021 - 01/2021
2	AntithrombinsIBA 02/2021 - 12/2020
2	Protein SIBA 02/2021 - 12/2020
2	Hydroxychloroquine (Plaquenil)FDA LinkGeneric 01/2021 - 12/2020
2	Blood Coagulation Factors (Coagulation Factor)IBA 12/2020 - 12/2012
2	Fibrinogen (Factor I)FDA Link 12/2020 - 12/2012
2	MicroRNAs (MicroRNA)IBA 01/2018 - 11/2017
2	Imatinib Mesylate (Gleevec)FDA Link 01/2018 - 01/2017
2	Complement System Proteins (Complement)IBA 08/2017 - 09/2015
2	Dacarbazine (DIC)FDA LinkGeneric 02/2017 - 03/2014
2	Therapeutic UsesIBA 06/2011 - 09/2009
2	Carbonic Anhydrase IXIBA 06/2011 - 11/2006
2	Vasodilator Agents (Vasodilators)IBA 04/2010 - 09/2009
2	Carbonic Anhydrase InhibitorsIBA 06/2008 - 01/2007
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2008 - 01/2006

Therapy/Procedure

8	Therapeutics 08/2021 - 08/2003
2	Duration of Therapy 01/2021 - 12/2020
2	Intravenous Administration 01/2017 - 10/2009